Post-Marketing Surveillance: Ensuring Drug Safety in Real-World Populations

High-Impact Journals

Interesting topics

Ensuring Drug Safety in Real-World Populations

Table of Content

1. Methodologies in Post-Marketing Surveillance
2. Regulatory Frameworks
3. Challenges in Post-Marketing Surveillance
4. Emerging Trends in Post-Marketing Surveillance
5. Case Studies
7. Conclusion

Post-Marketing Surveillance (PMS) is a critical and vital step of drug development, potentially the most important part of drug development. It entails the act of surveillance for drug safety and efficacy after a drug has been approved for use in the general population. It is different from pre-market clinical evaluations in that PMS centres on the goal of gathering observational data to identify adverse and long-term events that were not previously identified in the clinical evaluations. [1]

1. Methodologies in Post-Marketing Surveillance

PMS utilizes several strategies to monitor the safety of drugs. [2]

Spontaneous Reporting Systems (SRS): Adverse Drug Reactions (ADRs) are reported voluntarily by health care providers and patients. often documented through case report writing.
Cohort Studies: Follow-up studies observing patients who take a drug are compared to non-exposed individuals without the drug, providing valuable data for clinical literature review. [3]
Case-Control Studies: Studies that examine patients who had an ADR and examine similar patients who did not experience the ADR to estimate a risk factor for the adverse drug reaction.
Registry-based Studies: Studies that utilize patient registries to study long-term outcomes and similar adverse drug events, helping create patient education materials and patient education content.
Electronic Health Record (EHR) Mining: Large sources of EHR systems that can be mined for adverse events and safety signals.

2. Regulatory Frameworks

Worldwide regulatory agencies establish guidelines for PMS:

S. Food and Drug Administration (FDA). The FDA administers a system for reporting adverse events, the Adverse Event Reporting System (FAERS), to oversee post-marketing safety of drugs.
European Medicines Agency (EMA). The EMA administers the Pharmacovigilance Risk Assessment Committee (PRAC), where the risks associated with medicines are evaluated and monitored by the committee.
World Health Organization (WHO). The WHO has the Uppsala Monitoring Centre that leads international efforts to monitor drug safety.

3. Challenges in Post-Marketing Surveillance

PMS, though rated as highly important, grapples with several challenges: [4]

ADR Underreporting: Healthcare professionals and/or patients may not report an adverse event due to unawareness or time restraints.
Data Quality and Data Completeness: When data is either incomplete or inaccurate, it can complicate the safety signal or identification.
Signal Detection: Distinguishing a true safety signal from a coincidental finding requires rigorous statistical methods.
Global Variability: Variation in healthcare systems and reporting practices between countries may influence PMS data variability.

4. Emerging Trends in Post-Marketing Surveillance

Technological advancement is changing the landscape of PMS: [5]

Artificial Intelligence (AI) and Machine Learning (ML): These technologies can use big data to enhance the identification of potential ADRs. ScienceDirect
Real-World Evidence (RWE): Evidence from actual clinical practices, like insurance claims and patient registries, provides valuable data about drug performance outside of clinical studies.
Patient-Reported Outcomes (PROs): Information provided directly from patients about their health status and treatment experience adds to the knowledge of the drug’s effect.

5. Case Studies

Case Study 1: Rofecoxib

Rofecoxib, a non-steroidal anti-inflammatory drug, was taken off the market in 2004 after post-marketing monitoring showed an increased risk of cardiovascular events. This case demonstrates the need for ongoing monitoring following drug approval. [6]

Case Study 2: Thalidomide

Thalidomide was originally approved for use as a sedative but was withdrawn after it was associated with birth defects. However, PMS was later found to have efficacy for the treatment of leprosy and multiple myeloma, prompting a reintroduction under restricted conditions.[7]

Connect with us to explore how we can support you in maintaining academic integrity and enhancing the visibility of your research across the world!

Conclusion

PMS is a critical component of pharmacovigilance that verifies the continuing safety and effectiveness of pharmaceutical products in the general population. PMS detects and mitigates adverse drug reactions that may not have been manifestly observable in clinical trials, thus ensuring the safety of the public health and providing valuable information to support regulatory decisions. continuous technological innovation and data analytics, along with physician training, customized writing, and patient education content, are promising approaches to making PMS systems more proactive and responsive to safety issues that arise

Post-Marketing Surveillance: Ensuring Drug Safety in Real-World Populations. Our Pubrica consultants are here to guide you. [Get Expert Publishing Support] or [Schedule a Free Consultation]

References

Raj, N., Fernandes, S., Charyulu, N. R., Dubey, A., G S, R., & Hebbar, S. (2019). Postmarket surveillance: a review on key aspects and measures on the effective functioning in the context of the United Kingdom and Canada. Therapeutic advances in drug safety, 10, 2042098619865413. https://doi.org/10.1177/2042098619865413
Zinchenko, V. V., Arzamasov, K. M., Chetverikov, S. F., Maltsev, A. V., Novik, V. P., Akhmad, E. S., Sharova, D. E., Andreychenko, A. E., Vladzymyrskyy, A. V., & Morozov, S. P. (2022). Methodology for Conducting Post-Marketing Surveillance of Software as a Medical Device Based on Artificial Intelligence Technologies. Sovremennye tekhnologii v meditsine, 14(5), 15–23. https://doi.org/10.17691/stm2022.14.5.02
Setia M. S. (2016). Methodology Series Module 1: Cohort Studies. Indian journal of dermatology, 61(1), 21–25. https://doi.org/10.4103/0019-5154.174011
French, D. D., Margo, C. E., & Campbell, R. R. (2015). Enhancing postmarketing surveillance: continuing challenges. British journal of clinical pharmacology, 80(4), 615–617. https://doi.org/10.1111/bcp.12658
Alomar, M., Tawfiq, A. M., Hassan, N., & Palaian, S. (2020). Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Therapeutic advances in drug safety, 11, 2042098620938595. https://doi.org/10.1177/2042098620938595
Garner, S. E., Fidan, D. D., Frankish, R., & Maxwell, L. (2005). Rofecoxib for osteoarthritis. The Cochrane database of systematic reviews, 2005(1), CD005115. https://doi.org/10.1002/14651858.CD005115
Rehman, W., Arfons, L. M., & Lazarus, H. M. (2011). The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development. Therapeutic advances in hematology, 2(5), 291–308. https://doi.org/10.1177/2040620711413165